AB-Biotics provided earnings guidance for the full year of 2013. For the period, the company forecasts a net loss of EUR 1.8 million (USD 2.475 million), significantly below the EUR 3.9 million expectations of analysts. The company made an important effort to adjust its operating costs, which went down by 35%, with loss before interest, tax, depreciation and amortisation (LBITDA) seen at EUR 1.56 million.